Vaxcyte (PCVX) Other Non-Current Assets (2019 - 2026)

Vaxcyte (PCVX) has reported Other Non-Current Assets for 8 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 11.14% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 11.14% YoY), while the FY2025 annual figure was $1.5 million, up 11.31% from the prior year.
• Other Non-Current Assets steadied at $1.5 million in Q1 2026 per PCVX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $5.7 million in Q1 2022 and bottomed at $871000.0 in Q3 2022.
• Historically, Other Non-Current Assets has averaged $1.8 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 523.31% — and 2023, when it sank 84.63%.
• Vaxcyte's Other Non-Current Assets stood at $871000.0 in 2022, then rose by 26.64% to $1.1 million in 2023, then grew by 19.4% to $1.3 million in 2024, then rose by 11.31% to $1.5 million in 2025, then changed by 0.0% to $1.5 million in 2026.
• Business Quant data shows PCVX's Other Non-Current Assets at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.